How has been the historical performance of Brawn Biotech?

Answer:The historical performance of Brawn Biotech shows a mixed financial picture with a net profit of 0.19 Cr for the year ending March 2023, alongside total operating income of 0.48 Cr. The company reported an operating profit (PBDIT) of 0.24 Cr, indicating a gross profit margin of 50.0% and a profit after tax (PAT) margin of 39.58%. The earnings per share (EPS) stood at 0.39, while the diluted EPS was slightly lower at 0.38.

Breakdown:
In the fiscal year ending March 2023, Brawn Biotech achieved net sales of 0.48 Cr, with total operating income matching this figure. The company incurred total expenditures of 0.48 Cr, leading to an operating profit (PBDIT) of 0.24 Cr after accounting for other income. The profit before tax was recorded at 0.22 Cr, resulting in a profit after tax of 0.19 Cr. The company's total assets were valued at 14.13 Cr, with total liabilities at 14.13 Cr as well, indicating a balanced sheet. The shareholder's funds decreased to 5.07 Cr from 6.31 Cr the previous year, reflecting a decline in reserves. Cash flow activities showed no movement, with net cash inflow/outflow remaining at zero. Overall, while Brawn Biotech reported a profit, the decline in shareholder's funds and stagnant cash flow may raise concerns about its financial stability moving forward.